Showing 4901-4910 of 20470 results for "".
- Povorcitinib Shows Durable Efficacy in HS in Phase 3 STOP-HS Trialshttps://reachmd.com/news/povorcitinib-shows-durable-efficacy-in-hs-in-phase-3-stop-hs-trials/2486420/Late-breaking results from the Phase 3 STOP-HS1 and STOP-HS2 trials presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting showed that povorcitinib, an oral JAK1-selective inhibitor, achieved sustained efficacy and a manageable safety profile through 54 weeks in patients with
- Litifilimab Advances CLE Treatment With Positive Phase 2 Datahttps://reachmd.com/news/litifilimab-advances-cle-treatment-with-positive-phase-2-data/2486419/Late-breaking data from the Phase 2 AMETHYST Part A trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting show that litifilimab, a monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), improved disease activity in patients with cutaneous lupus erythemato
- Prurigo Nodularis Linked to Elevated Cardiovascular Risk, Expanding View of Systemic Diseasehttps://reachmd.com/news/prurigo-nodularis-linked-to-elevated-cardiovascular-risk-expanding-view-of-systemic-disease/2486416/Growing evidence indicates prurigo nodularis (PN) is associated with increased cardiovascular risk, reinforcing the disease’s systemic nature and the potential consequences of untreated inflammation, according to a talk by Shawn Kwatra, MD, at the 2026 American Academy of Dermatology Annual Meeti
- Study Links MRGPRX3 Expression to Chronic Pruritus in PN and ADhttps://reachmd.com/news/study-links-mrgprx3-expression-to-chronic-pruritus-in-pn-and-ad/2486413/In a prospective analysis of skin biopsies, investigators reported significantly elevated cutaneous MRGPRX3 expression in lesional prurigo nodularis (PN) and atopic dermatitis (AD), alongside a notable association between MRGPRX3-related gene mutations and Black pa
- What New Secukinumab Data Mean for HS Patients: A Q&A with Dr. April Armstronghttps://reachmd.com/news/what-new-secukinumab-data-mean-for-hs-patients-a-qa-with-dr-april-armstrong/2486412/In the following Q&A, Dr. April Armstrong, professor and chief of dermatology at UCLA and a study coauthor, talks with Practical Dermatology about the importance of new secukinumab data for patients with hidradenitis suppurativa (HS). Speaking on UCB's recently announced top
- Study: Dermatologists Rarely Prescribe GLP-1 Agents in Psoriasis, HS Cohorthttps://reachmd.com/news/study-dermatologists-rarely-prescribe-glp-1-agents-in-psoriasis-hs-cohort/2486411/A new retrospective review identified a significant gap in care between eligibility for glucagon-like peptide-1 receptor agonists (GLP-1RAs) and real-world utilization among patients with psoriasis and hidradenitis suppurativa (HS).
- AAD 2026: CO2 Laser Resurfacing Linked to Transient Microbiome Shiftshttps://reachmd.com/news/aad-2026-co2-laser-resurfacing-linked-to-transient-microbiome-shifts/2486399/New findings presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, provide insight into dynamic microbiome changes following ablative CO2 laser resurfacing and their relationship to wound healing. In this monocentric, double-blind, rando
- AAD 2026: Oral Supplement Shows Gains in Hair Strength, Collagen VIIhttps://reachmd.com/news/aad-2026-oral-supplement-shows-gains-in-hair-strength-collagen-vii/2486396/New data presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, evaluated a nutraceutical approach to improving hair strength through collagen VII upregulation and mechanical resistance outcomes. The study assessed a daily oral supplement containing turmer
- Cannabis Use Linked to Lower BCC Risk, No Change in Melanoma or cSCC: Studyhttps://reachmd.com/news/cannabis-use-linked-to-lower-bcc-risk-no-change-in-melanoma-or-cscc/2486395/Cannabis use was linked with decreased incidince of basal cell carcinoma (BCC), but not cutaneous squamous cell carcinoma (cSCC) or malignant melanoma (MM), according to results from a newly presented poster. Researchers for t
- Drug-Coated Balloons Show Promise Over Stents in Coronary Bifurcation Side Branch Lesionshttps://reachmd.com/news/drug-coated-balloons-show-promise-over-stents-in-coronary-bifurcation-side-branch-lesions/2486388/The optimal strategy for managing side branch lesions in true coronary bifurcations has long challenged interventional cardiologists, particularly given concerns surrounding permanent metallic implants. A new syste